Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00004125 |
Recruitment Status :
Completed
First Posted : August 25, 2003
Last Update Posted : June 15, 2023
|
Sponsor:
Eastern Cooperative Oncology Group
Collaborators:
National Cancer Institute (NCI)
North Central Cancer Treatment Group
SWOG Cancer Research Network
Cancer and Leukemia Group B
Information provided by:
Eastern Cooperative Oncology Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | May 2007 |
Actual Study Completion Date : | November 2016 |
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Sparano JA, Wang M, Martino S, et al.: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-48, 2005.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):